← All trials
NCT00813696
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2002
- Primary completion
- Mar 1, 2009
- Completion date
- Sep 1, 2009
- First posted
- —
- Last posted
- —
- Enrollment
- 400
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Istituti Tumori Giovanni Paolo IILead sponsor
- Fondazione Giovanni PascaleOverall official - principal investigator
- University of Campania Luigi VanvitelliOverall official - principal investigator
- Istituti Tumori Giovanni Paolo IIOverall official - principal investigator
- University of MilanOverall official - principal investigator
- University of VeronaOverall official - principal investigator
- University of FlorenceOverall official - principal investigator
- Gruppo Oncologico Italia MeridionaleCollaborator
- Gruppo Italiano per lo studio dei Carcinomi dell'Apparato DigerenteCollaborator
- Gruppo Oncologico Italiano di Ricerca ClinicaCollaborator
- University of Roma La SapienzaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.